At ESMO 2024, Bayer will present key results from the Phase III ARANOTE trial on NUBEQA® (darolutamide) for metastatic hormone-sensitive prostate cancer and the PEACE-III study of XOFIGO® (radium-223) ...

the European leader in pharmaceutical wholesale and retail pharmacy. This initiative aims to transform the operations of PHOENIX group, bringing cutting-edge technology and operational excellence to ...

This article highlights several inspiring men and women working across academia and industry who are breaking barriers and ...

Bong Joon-woo, a professor of colorectal and analgesic surgery at Korea University Guro Hospital, recently won the 'Best presented paper award'' at the 43rd European Society of Surgeons (ESSO)' held ...

This industry symposium took place during the European Society for Medical Oncology (ESMO) Congress held in Barcelona, Spain, 13 th –17 th September 2024. Rolfo has received advisory board fees from ...

We were particularly pleased to see the momentum now being established in our oncology business ... asthma was front and center at the European Respiratory Society Congress and simultaneously ...

Maybe even more concretely, Evaxion Biotech recently presented one-year data from their phase 2 trial of EVX-01, an AI-designed personalized cancer vaccine, at the European Society for Medical ...

Investors in the cell therapy industry are actively looking into solid tumours, autoimmune indications and novel engineering as the best place to allocate their money and resources. This, along ...

The report by the European Social Insurance Platform (ESIP ... In France, for instance, oncology drugs make up 29% of out-patient pharmaceutical spending, with an annual growth rate of 11%.

Katherine Van Loon, MD, MPH, has been appointed as the next editor-in-chief of JCO Global Oncology (JCO GO), an American Society of Clinical Oncology (ASCO) journal.